KR20250165665A - Glp-1 수용체 및 아밀린 수용체의 공동-작용제 - Google Patents
Glp-1 수용체 및 아밀린 수용체의 공동-작용제Info
- Publication number
- KR20250165665A KR20250165665A KR1020257037256A KR20257037256A KR20250165665A KR 20250165665 A KR20250165665 A KR 20250165665A KR 1020257037256 A KR1020257037256 A KR 1020257037256A KR 20257037256 A KR20257037256 A KR 20257037256A KR 20250165665 A KR20250165665 A KR 20250165665A
- Authority
- KR
- South Korea
- Prior art keywords
- ethoxy
- receptor
- glp
- amino
- acetyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20215291.4 | 2020-12-18 | ||
| EP20215291 | 2020-12-18 | ||
| EP21154668 | 2021-02-02 | ||
| EP21154668.4 | 2021-02-02 | ||
| EP21179810.3 | 2021-06-16 | ||
| EP21179810 | 2021-06-16 | ||
| KR1020247015294A KR102884383B1 (ko) | 2020-12-18 | 2021-12-17 | Glp-1 수용체 및 아밀린 수용체의 공동-작용제 |
| PCT/EP2021/086494 WO2022129526A1 (en) | 2020-12-18 | 2021-12-17 | Co-agonists of the glp-1 and amylin receptors |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247015294A Division KR102884383B1 (ko) | 2020-12-18 | 2021-12-17 | Glp-1 수용체 및 아밀린 수용체의 공동-작용제 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250165665A true KR20250165665A (ko) | 2025-11-26 |
Family
ID=79024591
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257037256A Pending KR20250165665A (ko) | 2020-12-18 | 2021-12-17 | Glp-1 수용체 및 아밀린 수용체의 공동-작용제 |
| KR1020237002759A Active KR102667196B1 (ko) | 2020-12-18 | 2021-12-17 | Glp-1 수용체 및 아밀린 수용체의 공동-작용제 |
| KR1020247015294A Active KR102884383B1 (ko) | 2020-12-18 | 2021-12-17 | Glp-1 수용체 및 아밀린 수용체의 공동-작용제 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237002759A Active KR102667196B1 (ko) | 2020-12-18 | 2021-12-17 | Glp-1 수용체 및 아밀린 수용체의 공동-작용제 |
| KR1020247015294A Active KR102884383B1 (ko) | 2020-12-18 | 2021-12-17 | Glp-1 수용체 및 아밀린 수용체의 공동-작용제 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12054528B2 (https=) |
| EP (1) | EP4263581A1 (https=) |
| JP (1) | JP7554928B2 (https=) |
| KR (3) | KR20250165665A (https=) |
| CN (1) | CN116669753A (https=) |
| AU (2) | AU2021403851B2 (https=) |
| CA (1) | CA3201088A1 (https=) |
| CL (1) | CL2023001714A1 (https=) |
| CO (1) | CO2023008866A2 (https=) |
| IL (2) | IL303127A (https=) |
| MX (2) | MX2023005707A (https=) |
| MY (1) | MY209195A (https=) |
| PE (1) | PE20231659A1 (https=) |
| TW (2) | TWI850611B (https=) |
| WO (1) | WO2022129526A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| WO2023110833A1 (en) | 2021-12-13 | 2023-06-22 | Novo Nordisk A/S | Pharmaceutical formulations comprising a cyclodextrin |
| WO2023187067A1 (en) | 2022-03-30 | 2023-10-05 | Novo Nordisk A/S | Formulation method |
| WO2024022465A1 (zh) * | 2022-07-29 | 2024-02-01 | 杭州九源基因工程有限公司 | 一种人胰淀素多肽衍生物及其用途 |
| IL318291A (en) * | 2022-08-05 | 2025-03-01 | Univ Indiana Res & Tech Corp | Glucagon-like peptide 1 receptor antibodies |
| US12116388B2 (en) | 2022-12-22 | 2024-10-15 | Novo Nordisk A/S | Amylin receptor agonists |
| WO2024179606A1 (zh) * | 2023-03-02 | 2024-09-06 | 甘李药业股份有限公司 | 一种glp-1化合物的医药用途 |
| KR20240176455A (ko) | 2023-06-15 | 2024-12-24 | 노보 노르디스크 에이/에스 | 시클로덱스트린을 포함하는 약학적 제형 |
| TW202540155A (zh) | 2023-11-30 | 2025-10-16 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1、gip及澱粉素受體之三重促效劑 |
| AU2025214636A1 (en) * | 2024-01-29 | 2026-01-29 | Immunwork Inc. | Pharmaceutical formulation of glucagon-like peptide -1 receptor agonist peptide for sublingual delivery |
| EP4721760A1 (en) | 2024-10-07 | 2026-04-08 | Adocia | Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| WO2025172605A1 (en) | 2024-02-16 | 2025-08-21 | Adocia | Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| EP4721761A1 (en) | 2024-10-07 | 2026-04-08 | Adocia | Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| EP4603079A1 (en) | 2024-02-16 | 2025-08-20 | Adocia | Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| EP4684802A1 (en) | 2024-07-23 | 2026-01-28 | Adocia | Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| EP4684801A1 (en) | 2024-07-23 | 2026-01-28 | Adocia | Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| EP4603080A1 (en) | 2024-02-16 | 2025-08-20 | Adocia | Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| WO2025172606A1 (en) | 2024-02-16 | 2025-08-21 | Adocia | Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| WO2025242620A1 (en) * | 2024-05-20 | 2025-11-27 | Medimmune Limited | Polypeptide combinations and uses thereof |
| WO2025264979A1 (en) * | 2024-06-21 | 2025-12-26 | I2O Therapeutics, Inc. | Compositions comprising pharmaceutically acceptable salts and other derivatives of dual glp-1/amylin receptor agonists and uses thereof |
| WO2026008836A1 (en) * | 2024-07-05 | 2026-01-08 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| WO2026013265A1 (en) | 2024-07-12 | 2026-01-15 | Novo Nordisk A/S | Novel dipeptide acylating agents |
| CN120305390B (zh) * | 2025-06-18 | 2025-10-03 | 杭州思诺达医药科技有限责任公司 | 一种降血糖的药物制剂 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994008006A1 (en) | 1992-09-30 | 1994-04-14 | Zymogenetics, Inc. | Human calcitonin receptor |
| BR122019021416A2 (https=) | 2003-09-19 | 2019-12-21 | ||
| NZ579621A (en) * | 2004-02-11 | 2011-03-31 | Amylin Pharmaceuticals Inc | Hybrid polypeptides with selectable properties |
| WO2007022123A2 (en) | 2005-08-11 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| WO2007109354A2 (en) * | 2006-03-21 | 2007-09-27 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
| EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| WO2009030771A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| EP2416797A4 (en) | 2009-04-10 | 2013-04-24 | Amylin Pharmaceuticals Llc | AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE |
| EP2504021A4 (en) * | 2009-11-23 | 2013-05-15 | Amylin Pharmaceuticals Llc | Polypeptide conjugate |
| JP6006118B2 (ja) * | 2009-12-16 | 2016-10-12 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アナログ及び誘導体 |
| WO2011084808A2 (en) | 2009-12-21 | 2011-07-14 | Amunix Operating Inc. | Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases |
| SI2651398T1 (en) | 2010-12-16 | 2018-04-30 | Novo Nordisk A/S | SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS |
| EP2714069A4 (en) | 2011-05-25 | 2015-06-24 | Amylin Pharmaceuticals Llc | LONG-TERM CONJUGATES WITH TWO HORMONES |
| WO2012160212A1 (en) | 2011-05-25 | 2012-11-29 | Camurus Ab | Peptide controlled-release formulations |
| JP6121992B2 (ja) | 2011-06-10 | 2017-04-26 | ノヴォ ノルディスク アー／エス | ポリペプチド |
| AU2012311484B2 (en) * | 2011-09-23 | 2017-04-13 | Novo Nordisk A/S | Novel glucagon analogues |
| HRP20181447T1 (hr) | 2012-03-22 | 2018-11-02 | Novo Nordisk A/S | Pripravci glp-1 peptida i njihova priprava |
| JP6517690B2 (ja) | 2012-06-20 | 2019-05-22 | ノヴォ ノルディスク アー／エス | ペプチド及び送達剤を含む錠剤製剤 |
| JP6475233B2 (ja) | 2013-06-20 | 2019-02-27 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体及びその使用 |
| CN104558198A (zh) | 2014-07-25 | 2015-04-29 | 成都贝爱特生物科技有限公司 | GLP-1类似物和amylin类似物的融合蛋白制备及其用途 |
| WO2016034604A1 (en) | 2014-09-04 | 2016-03-10 | Novo Nordisk A/S | Novel amylin and calcitonin receptor agonist |
| JP6730278B2 (ja) | 2014-11-27 | 2020-07-29 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体及びその使用 |
| WO2016097108A1 (en) | 2014-12-17 | 2016-06-23 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| CN105367664B (zh) * | 2015-11-04 | 2019-09-20 | 成都贝爱特生物科技有限公司 | 激活GLP-1受体和Amylin受体双功能作用的融合蛋白制备及其用途 |
| BR102015031283A2 (pt) | 2015-12-14 | 2018-09-18 | Univ Rio De Janeiro | Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento |
| ES2828526T3 (es) | 2016-11-07 | 2021-05-26 | Novo Nordisk As | Esteres activos DCHBS de compuestos PEG y sus usos |
| CN108424460A (zh) | 2017-02-13 | 2018-08-21 | 成都贝爱特生物科技有限公司 | GLP-1类似物和davalintide类似物的融合蛋白制备及其用途 |
| JP6898518B2 (ja) | 2018-02-02 | 2021-07-07 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物 |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| CN115461044B (zh) | 2020-04-29 | 2025-06-10 | 诺和诺德股份有限公司 | 包含glp-1激动剂和组氨酸的固体组合物 |
-
2021
- 2021-12-16 TW TW110147258A patent/TWI850611B/zh active
- 2021-12-16 TW TW113124717A patent/TW202440619A/zh unknown
- 2021-12-17 MX MX2023005707A patent/MX2023005707A/es unknown
- 2021-12-17 CN CN202180085551.0A patent/CN116669753A/zh active Pending
- 2021-12-17 IL IL303127A patent/IL303127A/en unknown
- 2021-12-17 KR KR1020257037256A patent/KR20250165665A/ko active Pending
- 2021-12-17 MY MYPI2023002756A patent/MY209195A/en unknown
- 2021-12-17 EP EP21831066.2A patent/EP4263581A1/en active Pending
- 2021-12-17 CA CA3201088A patent/CA3201088A1/en active Pending
- 2021-12-17 IL IL325793A patent/IL325793A/en unknown
- 2021-12-17 KR KR1020237002759A patent/KR102667196B1/ko active Active
- 2021-12-17 WO PCT/EP2021/086494 patent/WO2022129526A1/en not_active Ceased
- 2021-12-17 KR KR1020247015294A patent/KR102884383B1/ko active Active
- 2021-12-17 PE PE2023001880A patent/PE20231659A1/es unknown
- 2021-12-17 AU AU2021403851A patent/AU2021403851B2/en active Active
- 2021-12-17 JP JP2023528227A patent/JP7554928B2/ja active Active
-
2022
- 2022-12-19 US US18/084,088 patent/US12054528B2/en active Active
-
2023
- 2023-05-16 MX MX2025000872A patent/MX2025000872A/es unknown
- 2023-06-13 CL CL2023001714A patent/CL2023001714A1/es unknown
- 2023-07-04 CO CONC2023/0008866A patent/CO2023008866A2/es unknown
-
2024
- 2024-02-29 US US18/591,754 patent/US20240279299A1/en active Pending
-
2025
- 2025-10-09 AU AU2025248685A patent/AU2025248685A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240279299A1 (en) | 2024-08-22 |
| IL303127A (en) | 2023-07-01 |
| US20230331803A1 (en) | 2023-10-19 |
| KR102667196B1 (ko) | 2024-05-27 |
| PE20231659A1 (es) | 2023-10-17 |
| AU2025248685A1 (en) | 2025-10-30 |
| CL2023001714A1 (es) | 2024-01-05 |
| AU2021403851B2 (en) | 2025-09-25 |
| KR20230019499A (ko) | 2023-02-08 |
| JP2023553591A (ja) | 2023-12-25 |
| IL325793A (en) | 2026-03-01 |
| TW202227474A (zh) | 2022-07-16 |
| KR20240074867A (ko) | 2024-05-28 |
| TWI850611B (zh) | 2024-08-01 |
| CA3201088A1 (en) | 2022-06-23 |
| WO2022129526A1 (en) | 2022-06-23 |
| AU2021403851A9 (en) | 2025-03-20 |
| US12054528B2 (en) | 2024-08-06 |
| MX2023005707A (es) | 2023-07-31 |
| CO2023008866A2 (es) | 2023-10-09 |
| KR102884383B1 (ko) | 2025-11-14 |
| CN116669753A (zh) | 2023-08-29 |
| JP7554928B2 (ja) | 2024-09-20 |
| EP4263581A1 (en) | 2023-10-25 |
| AU2021403851A1 (en) | 2023-06-15 |
| TW202440619A (zh) | 2024-10-16 |
| MY209195A (en) | 2025-06-26 |
| MX2025000872A (es) | 2025-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102884383B1 (ko) | Glp-1 수용체 및 아밀린 수용체의 공동-작용제 | |
| TWI707865B (zh) | Gip衍生物及其用途 | |
| KR102446310B1 (ko) | 경구 전달에 적합한 glp-1 및 gip 수용체에서의 공-작용제 | |
| TW202415675A (zh) | 腸促胰島素(incretin)類似物及其用途 | |
| KR20230042019A (ko) | Glp-1 및 gip 수용체 공동-작용제 | |
| CN121975020A (en) | Co-agonists of GLP-1 and the amylin receptor | |
| CN121991249A (zh) | Glp-1和胰淀素受体的共激动剂 | |
| CN121991202A (zh) | Glp-1和胰淀素受体的共激动剂 | |
| BR122024023347A2 (pt) | Coagonistas dos receptores glp-1 e amilina, formulação farmacêutica compreendendo os ditos coagonistas e uso terapêutico dos mesmos | |
| JP7755031B2 (ja) | Ｇｌｐ－１、ｇｉｐ、およびアミリン受容体の三重作動薬 | |
| US12116388B2 (en) | Amylin receptor agonists | |
| EP4638480A1 (en) | Amylin receptor agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |